|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-9.42/-7.90
|
企业价值
383.65M
|
资产负债 |
每股账面净值
19.17
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/11 16:38 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generatinga portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |